Adult; Anti-HIV Agents/therapeutic use; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral/genetics; Female; Genotype; HIV Infections/drug therapy; HIV-1/genetics; Humans; Logistic Models; Male; Middle Aged; Mutation; Odds Ratio; Retrospective Studies; Rwanda; Tenofovir/therapeutic use; Treatment Failure; Viral Load; Young Adult; HIV; Tenofovir; VIH; drug resistance; fallo viral; resistencia a medicamentos; resistance aux medicaments; viral failure; echec viral
Abstract :
[en] OBJECTIVE: To evaluate HIV drug resistance (HIVDR) and determinants of virological failure in a large cohort of patients receiving first-line tenofovir-based antiretroviral therapy (ART) regimens. METHODS: A nationwide retrospective cohort from 42 health facilities was assessed for virological failure and development of HIVDR mutations. Data were collected at ART initiation and at 12 months of ART on patients with available HIV-1 viral load (VL) and ART adherence measurements. HIV resistance genotyping was performed on patients with VL >/=1000 copies/ml. Multiple logistic regression was used to determine factors associated with treatment failure. RESULTS: Of 828 patients, 66% were women, and the median age was 37 years. Of the 597 patients from whom blood samples were collected, 86.9% were virologically suppressed, while 11.9% were not. Virological failure was strongly associated with age <25 years (adjusted odds ratio [aOR]: 6.4; 95% confidence interval [CI]: 3.2-12.9), low adherence (aOR: 2.87; 95% CI: 1.5-5.0) and baseline CD4 counts <200 cells/mul (aOR 3.4; 95% CI: 1.9-6.2). Overall, 9.1% of all patients on ART had drug resistance mutations after 1 year of ART; 27% of the patients who failed treatment had no evidence of HIVDR mutations. HIVDR mutations were not observed in patients on the recommended second-line ART regimen in Rwanda. CONCLUSIONS: The last step of the UNAIDS 90-90-90 target appears within grasp, with some viral failures still due to non-adherence. Nonetheless, youth and late initiators are at higher risk of virological failure. Youth-focused programmes could help prevent further drug HIVDR development.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Mills EJ, Bakanda C, Birungi J et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011: 155: 209–216.
Nsanzimana S, Remera E, Kanters S et al. Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study. Lancet Glob Health 2015: 3: e169–e177.
Nsanzimana S. Rwanda Experience towards HIV treatment as prevention. In: International Treatment as Prevention Workshop. Vancouver, Canada, 2013.
Hamers RL, Sigaloff KC, Kityo C, Mugyenyi P, de Wit TF. Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. Curr Opin HIV AIDS 2013: 8: 19–26.
Lee GQ, Bangsberg DR, Muzoora C et al. Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda. AIDS Res Hum Retroviruses 2014: 30: 896–906.
Stadeli KM, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther 2013: 18: 115–123.
Rusine J, Asiimwe-Kateera B, van de Wijgert J et al. Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda. PLoS ONE 2013: 8: e64345.
Mutwa PR, Boer KR, Rusine J et al. Long-term effectiveness of combination antiretroviral therapy and prevalence of HIV drug resistance in HIV-1-infected children and adolescents in Rwanda. Pediatr Infect Dis J 2014: 33: 63–69.
TRAC and Ministry of Health of Rwanda. REPUBLIC OF RWANDA Guide for Care of People Living with HIV in Rwanda. Kigali-Rwanda, 2007: 57–78.
TRAC and Ministry of Health of Rwanda. Guidelines for the provision of comprehensive care to persons infected by HIV in Rwanda. Kigali-Rwanda, 2009:31–37.
Marconi VC, Sunpath H, Lu Z et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008: 46: 1589–1597.
Reynolds SJ, Kityo C, Mbamanya F et al. Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda. Antivir Ther 2009: 14: 293–297.
RBC/HIV Division. HIV and AIDS in Rwanda Projections Change. Ministry of Health: Kigali-Rwanda, 2010.
RBC/HIV Division. Annual Report on HIV AND AIDS July 2012–June 2013. Ministry of Health: Kigali-Rwanda, 2013.
Bertagnolio S, Penazzato M, Jordan MR, Persaud D, Mofenson LM, Bennett DE. World Health Organization generic protocol to assess drug-resistant HIV among children <18 months of age and newly diagnosed with HIV in resource-limited countries. Clin Infect Dis 2012: 54(Suppl 4): S254–S260.
Nsanzimana S, Ruton H, Lowrance DW et al. Cell phone-based and internet-based monitoring and evaluation of the National Antiretroviral Treatment Program during rapid scale-up in Rwanda: TRACnet, 2004–2010. J Acquir Immune Defic Syndr (1999) 2012: 59: e17–e23.
El-Khatib Z, Ekstrom AM, Ledwaba J et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS 2010: 24: 1679–1687.
UNAIDS. 90–90–90 – An ambitious treatment target to help end the AIDS epidemic. UNAIDS: Geneva, Switzerland, 2014.
World Health Organization. World Health Organization Global Strategy for the Surveillance and Monitoring of hiv Drug Resistance 2012. WHO press: Geneva, Switzerland, 2012.
Franke MF, Kaigamba F, Socci AR et al. Improved retention associated with community-based accompaniment for antiretroviral therapy delivery in rural Rwanda. Clin Infect Dis 2013: 56: 1319–1326.
Boileau C, Nguyen VK, Sylla M et al. Low prevalence of detectable HIV plasma viremia in patients treated with antiretroviral therapy in Burkina Faso and Mali. J Acquir Immune Defic Syndr (1999) 2008: 48: 476–484.
Wadonda-Kabondo N, Hedt BL, van Oosterhout JJ et al. A retrospective survey of HIV drug resistance among patients 1 year after initiation of antiretroviral therapy at 4 clinics in Malawi. Clin Infect Dis 2012: 54 (Suppl. 4): S355–S361.
Hassan AS, Nabwera HM, Mwaringa SM et al. HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study. AIDS Res Ther 2014: 11: 9.
Mutwa PR, Van Nuil JI, Asiimwe-Kateera B et al. Living situation affects adherence to combination antiretroviral therapy in HIV-infected adolescents in Rwanda: a qualitative study. PLoS ONE 2013: 8: e60073.
Fox MP, Sanne IM, Conradie F et al. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS 2010: 24: 2041–2050.
Ugbena R, Aberle-Grasse J, Diallo K et al. Virological response and HIV drug resistance 12 months after antiretroviral therapy initiation at 2 clinics in Nigeria. Clin Infect Dis 2012: 54 (Suppl. 4): S375–S380.
Castagna A, Danise A, Menzo S et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 2006: 20: 795–803.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.